The US FDA has tightened the use of Duchenne muscular dystrophy gene therapy after two teenage patients died from acute liver failure. The agency has now restricted eligibility, mandating stricter patient selection and additional safety precautions. Experts say while the therapy is a major scientific breakthrough for slowing progression, the recent fatalities highlight serious risks.